NOX 0.00% 10.0¢ noxopharm limited

Ann: Appendix 4C - quarterly, page-5

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,947 Posts.
    lightbulb Created with Sketch. 790
    mmmmmm. The appendix prooves it was not speculation. It was missing, and they needed to address that lack. Nothing has changed, however, they have moved their priority from what was once their flag ship trial. And there is nothing wrong with that as the data determines what comes first as a priority. Could not say it any clearer than the appendix ann.

    "We have been asked if the Company has dropped the CEP program from our list of clinical studies as it wasn’t mentioned in the latest Appendix 4C. The answer is, no, we haven’t. But it is not a priority. "

    CEP is not a priority.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
10.0¢
Change
0.000(0.00%)
Mkt cap ! $29.22M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
5 52445 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 14000 1
View Market Depth
Last trade - 09.52am 27/11/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.